Home > Healthcare > Medical Devices > Diagnostic Devices > critical care diagnostics market
Get a free sample of Critical Care Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Critical Care Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The rising the prevalence of chronic diseases and lifestyle-related disorders is a significant driver for market. These diagnostics enable healthcare providers to identify disease progression, monitor treatment efficacy, and make timely adjustments to treatment plans, improving patient outcomes.
The glucose diagnostic kits segment in the market will record USD 507.2 million by 2032, driven by the rising prevalence of diabetes and the importance of monitoring glucose levels in critical care settings.
Critical care diagnostics industry size was worth USD 1.3 billion in 2023 and will grow at 5.5% CAGR between 2024 and 2032 due to escalating prevalence of chronic diseases and infectious outbreaks coupled with the emphasis on early detection and intervention.
U.S. critical care diagnostics industry size will expand at 5.1% CAGR from 2024 to 2032, attributed to advanced healthcare infrastructure, extensive research and development activities, and a strong emphasis on technological innovation.
Key players operating in the critical care diagnostics industry are Danaher Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Hologic, Inc., Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Nihon Kohden Corporation, and Nova Biomedical, among others.